Theriva Biologics(NYSEMKT) TOVX

Market Cap$10.48M

Since IPO (2006)-100%

5 Year-100%

1 Year-46%

1 Month-9%

$0.23

-0.35%

-0.00Today

Theriva Biologics last closing stock price
Metric	Price	Date
Last close	USD 0.23	2026-08-04

Theriva Biologics stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+7%	USD 0.21	2026-07-28
1 month	-9%	USD 0.25	2026-07-02
3 month	-40.21%	USD 0.38	2026-05-06
Year to date	+8.56%	USD 0.21	2025-12-31
1 year	-46.12%	USD 0.42	2025-08-04
3 year	-98.61%	USD 16.41	2023-08-04
5 year	-99.82%	USD 127.08	2021-08-05
Since inception	-100%	USD 14,700.13	2006-11-01

Theriva Biologics Financials at a Glance

Market Cap

$10.48M

Revenue (TTM)

$300.00K

Net Income (TTM)

-$21.46M

EPS (TTM)

-$2.53

P/E Ratio

-0.09

Dividend

$0.00

Beta (Volatility)

0.95 (Low)

Dividend

$0.00

Beta (Volatility)

0.95 (Low)

Price

$0.23

Volume

211,954

Open

$0.23

Price

$0.23

Volume

211,954

Open

$0.23

Previous Close

$0.23

Daily Range

$0.23 - $0.23

52-Week Range

$0.16 - $0.86

Estimated Earnings Date

Aug 12, 2026

Dividend

$0.00

Beta (Volatility)

0.95 (Low)

Price

$0.23

Volume

211,954

Open

$0.23

Previous Close

$0.23

Daily Range

$0.23 - $0.23

52-Week Range

$0.16 - $0.86

Estimated Earnings Date

Aug 12, 2026

TOVX News

1 Biotech Soars While Another Crashes

Dave WilliamsonDec 9, 2011

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Theriva Biologics

Theriva Biologics develops medicines for cancer and gut health problems. Its main products aim to help patients with hard-to-treat cancers and those at risk of gut infections. The company’s treatments are designed for people with few other medical options.

Products and Services

Oncolytic Viruses: Engineered viruses (VCN-01, VCN-11, VCN-12) target and destroy cancer cells; no revenue contribution yet.
Microbiome Protection: SYN-004 and SYN-006 protect gut bacteria during antibiotic use; no revenue contribution yet.
Enzyme Therapy: SYN-020, an oral enzyme for gut and body diseases, now licensed to another company; no revenue contribution yet.
Manufacturing Platform: THERICEL cell line supports virus production for clinical trials; no revenue contribution yet.

Growth and Expansion

Acquired Theriva Biologics, S.L. (formerly VCN Biosciences) in 2022, shifting focus to cancer therapies.
Licensed SYN-020 to Rasayana Therapeutics in February 2026, securing milestone and royalty payments.
Formed research partnerships with University of Texas at Austin, Cedars-Sinai, and Washington University for clinical trials.
Received €2.28M grant from the Spanish government in 2025 to scale up manufacturing.
Reduced workforce by 32% in September 2025 to focus on cancer programs and cut costs.

What Makes Theriva Biologics Stand Out

The company specializes in oncolytic viruses that can be given by vein, aiming to reach tumors throughout the body. Its technology helps drugs and immune cells enter tumors more easily by breaking down barriers around cancer cells. Theriva’s focus on rare cancers and partnerships with research centers set it apart in a crowded field.

Five Things You Need to Know

No revenue in QQ3 2025, QQ3 2024, or QQ3 2023; pre-commercial stage.
Net loss was $4M in QQ3 2025, improving 43.7% from QQ3 2024.
Cash used in operations was $4M in QQ3 2025, flat year-over-year.
Cash and equivalents were $13.1M as of December 31, 2025.
Workforce dropped to 16 employees by March 2026 after restructuring.

Bottom Line

Theriva Biologics has shifted from gut health to cancer therapies, focusing on innovative virus-based treatments. The company remains pre-revenue and relies on partnerships and external funding to advance its pipeline.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Steven A. Shallcross, MBA, CPA

Website

www.therivabio.com

Headquarters

Rockville, MD 20850, US

TOVX Financials

Key Financial Metrics (TTM)

Gross Margin

92.00%

Operating Margin

-7245.00%

Net Income Margin

-7153.00%

Return on Equity

-178.29%

Return on Capital

-83.39%

Return on Assets

-56.10%

Earnings Yield

-11.11%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$10.48M

Shares Outstanding

45.89M

Volume

211.95K

Avg. Volume

6.48M

Financials (TTM)

Gross Profit

$276.00K

Operating Income

-$21.74M

EBITDA

-$21.35M

Operating Cash Flow

-$14.37M

Capital Expenditure

-$35.00K

Free Cash Flow

-$14.40M

Cash & ST Invst.

$14.43M

Total Debt

$3.69M

Theriva Biologics Performance Analysis

Theriva Biologics annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 0	N/A
2023	2023-12-31	USD 0	N/A
2024	2024-12-31	USD 0	N/A
2025	2025-12-31	USD 0	N/A

Theriva Biologics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	N/A
Q3	2025-09-30	N/A
Q4	2025-12-31	N/A
Q1	2026-03-31	N/A

Theriva Biologics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -32.66	-31.3%
2023	2023-12-31	USD -28.48	-12.8%
2024	2024-12-31	USD -19.03	-33.2%
2025	2025-12-31	USD -2.08	-89.1%

Theriva Biologics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	-24.5%
Q3	2025-09-30	76.7%
Q4	2025-12-31	78.2%
Q1	2026-03-31	49.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$300.00K

N/A

Gross Profit

$276.00K

N/A

Gross Margin

92.00%

N/A

Market Cap

$10.48M

N/A

Market Cap/Employee

$655.12K

N/A

Employees

N/A

Net Income

-$2.04M

+52.7%

EBITDA

-$2.02M

+53.8%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$14.43M

+44.1%

Total Debt

$3.69M

+29.4%

Accounts Receivable

$1.79M

+5.3%

Inventory

$0.00

N/A

Long Term Debt

$3.15M

+40.8%

Short Term Debt

$545.00K

-12.0%

Return on Assets

-56.10%

N/A

Return on Invested Capital

-77.67%

N/A

Free Cash Flow

-$2.46M

+48.4%

Operating Cash Flow

-$2.46M

+48.4%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

CMMBChemomab Therapeutics Ltd.

CMMBChemomab Therapeutics Ltd.$1.75+4.17%

BIVIBioVie Inc.

BIVIBioVie Inc.$2.04+11.48%

MLECMoolec Science S.A.

MLECMoolec Science S.A.$7.10-1.44%

GLMDGalmed Pharmaceuticals Ltd.

GLMDGalmed Pharmaceuticals Ltd.$0.58+0.80%

ELABPMGC Holdings Inc.

ELABPMGC Holdings Inc.$0.98-0.39%

NKGNNKGen Biotech, Inc. Common Stock

NKGNNKGen Biotech, Inc. Common Stock$0.01-49.50%

ISPCiSpecimen Inc.

ISPCiSpecimen Inc.$1.92-10.70%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

SPCXSpace Exploration Technologies

SPCXSpace Exploration Technologies$108.27-0.14%

NVDANvidia

NVDANvidia$219.22+0.03%

ONDSOndas

ONDSOndas$8.87+0.00%

PATHUiPath

PATHUiPath$13.82-0.02%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$7.77-0.04%

INTCIntel

INTCIntel$101.06+0.00%

SNAPSnap

SNAPSnap$5.33-0.08%

Questions About TOVX

What is the current price of Theriva Biologics?

Theriva Biologics is trading at $0.23 per share.

What is the 52-week range for Theriva Biologics?

Over the past 52 weeks, Theriva Biologics has traded between $0.16 and $0.86.

How much debt does Theriva Biologics have?

As of the most recent reporting period, Theriva Biologics reported total debt of $3.69M.

How much cash does Theriva Biologics have on hand?

Theriva Biologics reported $14.43M in cash and cash equivalents in its most recent financial results.

What is Theriva Biologics’s dividend yield?

Theriva Biologics does not currently have a dividend yield.

Theriva Biologics(NYSEMKT) TOVX

Theriva Biologics Financials at a Glance

TOVX News

1 Biotech Soars While Another Crashes

Is Coach a Rule Breaker?

eBay Made Easy

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Theriva Biologics

Products and Services

Growth and Expansion

What Makes Theriva Biologics Stand Out

Five Things You Need to Know

Bottom Line

TOVX Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Theriva Biologics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About TOVX

What is the current price of Theriva Biologics?

What is the 52-week range for Theriva Biologics?

How much debt does Theriva Biologics have?

How much cash does Theriva Biologics have on hand?

What is Theriva Biologics’s dividend yield?

Premium Investing Services